Robust COX-2-mediated prostaglandin response may drive arthralgia and bone destruction in patients with chronic inflammation post-chikungunya.


Journal

PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488

Informations de publication

Date de publication:
02 2021
Historique:
received: 06 12 2019
accepted: 07 01 2021
revised: 01 03 2021
pubmed: 18 2 2021
medline: 23 6 2021
entrez: 17 2 2021
Statut: epublish

Résumé

Patients following infection by chikungunya virus (CHIKV) can suffer for months to years from arthralgia and arthritis. Interestingly, methotrexate (MTX) a major immune-regulatory drug has proved to be of clinical benefit. We have previously shown that CHIKV can persist in the joint of one patient 18 months post-infection and plausibly driving chronic joint inflammation but through ill-characterized mechanisms. We have pursued our investigations and report novel histological and in vitro data arguing for a plausible role of a COX-2-mediated inflammatory response post-CHIKV. In the joint, we found a robust COX-2 staining on endothelial cells, synovial fibroblasts and more prominently on multinucleated giant cells identified as CD11c+ osteoclasts known to be involved in bone destruction. The joint tissue was also strongly stained for CD3, CD8, CD45, CD14, CD68, CD31, CD34, MMP2, and VEGF (but not for NO synthase and two B cell markers). Dendritic cells were rarely detected. Primary human synovial fibroblasts were infected with CHIKV or stimulated either by the synthetic molecule polyriboinosinic:polyribocytidylic acid (PIC) to mimic chronic viral infection or cytokines. First, we found that PIC and CHIKV enhanced mRNA expression of COX-2. We further found that PIC but not CHIKV increased the mRNA levels of cPLA2α and of mPGES-1, two other central enzymes in PGE2 production. IFNβ upregulated cPLA2α and COX-2 transcription levels but failed to modulated mPGES-1 mRNA expression. Moreover, PIC, CHIKV and IFNβ decreased mRNA expression of the PGE2 degrading enzyme 15-PGDH. Interestingly, MTX failed to control the expression of all these enzymes. In sharp contrast, dexamethasone was able to control the capacity of pro-inflammatory cytokines, IL-1β as well as TNFα, to stimulate mRNA levels of cPLA2α, COX-2 and mPGES-1. These original data argue for a concerted action of CHIKV (including viral RNA) and cytokines plausibly released from recruited leukocytes to drive a major COX-2-mediated PGE2 proinflammatory responses to induce viral arthritis.

Identifiants

pubmed: 33596205
doi: 10.1371/journal.pntd.0009115
pii: PNTD-D-19-01987
pmc: PMC7920362
doi:

Substances chimiques

Cytokines 0
IL1B protein, human 0
Interleukin-1beta 0
Prostaglandins 0
RNA, Messenger 0
TNF protein, human 0
Tumor Necrosis Factor-alpha 0
Cyclooxygenase 2 EC 1.14.99.1
Dinoprostone K7Q1JQR04M
Methotrexate YL5FZ2Y5U1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0009115

Déclaration de conflit d'intérêts

The authors have declared that no competing interest exist.

Références

J Immunol. 2009 Mar 15;182(6):3877-83
pubmed: 19265167
J Rheumatol. 1996 Dec;23(12):2092-7
pubmed: 8970046
J Clin Invest. 2010 Mar;120(3):894-906
pubmed: 20179353
Eur J Biochem. 2000 Nov;267(21):6428-34
pubmed: 11029586
PLoS Negl Trop Dis. 2018 Aug 3;12(8):e0006634
pubmed: 30074983
Stem Cells. 2014 Feb;32(2):521-33
pubmed: 24105952
PLoS Negl Trop Dis. 2012;6(3):e1446
pubmed: 22479654
J Immunol. 2007 Oct 1;179(7):4821-8
pubmed: 17878381
Clin Infect Dis. 2007 Jun 1;44(11):1401-7
pubmed: 17479933
Nat Rev Rheumatol. 2012 May 08;8(7):420-9
pubmed: 22565316
Fundam Clin Pharmacol. 2005 Jun;19(3):255-61
pubmed: 15910650
Arch Biochem Biophys. 2005 Mar 1;435(1):50-5
pubmed: 15680906
PLoS Negl Trop Dis. 2009;3(3):e389
pubmed: 19274071
Curr Opin Rheumatol. 2018 May;30(3):256-263
pubmed: 29389830
Cell Immunol. 2012;273(2):150-7
pubmed: 22285102
J Virol. 2012 Jul;86(13):7180-91
pubmed: 22514352
Carcinogenesis. 2006 Nov;27(11):2170-9
pubmed: 16632868
Br J Rheumatol. 1996 Aug;35(8):711-8
pubmed: 8761181
Br J Pharmacol. 1979 Mar;65(3):517-24
pubmed: 371730
Curr Infect Dis Rep. 2011 Jun;13(3):218-28
pubmed: 21465340
Expert Rev Anti Infect Ther. 2015 Mar;13(3):291-3
pubmed: 25537007
Virol J. 2016 Sep 02;13(1):150
pubmed: 27590311
J Rheumatol. 1996 Feb;23(2):226-9
pubmed: 8882023
Arthritis Rheum. 2005 Nov;52(11):3439-47
pubmed: 16255020
Clin Immunol. 2006 Jun;119(3):229-40
pubmed: 16540375
J Immunol. 1980 Jul;125(1):431-7
pubmed: 6155405
J Immunol. 2001 Jul 1;167(1):469-74
pubmed: 11418684
Neurosci Res. 2001 Dec;41(4):299-332
pubmed: 11755218
Viruses. 2019 Mar 22;11(3):
pubmed: 30909365
Br Med Bull. 1987 Apr;43(2):285-96
pubmed: 2825898
Curr Pharm Des. 2004;10(6):577-88
pubmed: 14965321
Br J Pharmacol. 2002 May;136(2):287-95
pubmed: 12010778
Arthritis Res Ther. 2012 May 22;14(3):R121
pubmed: 22616846
Viruses. 2018 May 30;10(6):
pubmed: 29849008
Inflammation. 1979 Jul;3(3):243-51
pubmed: 478595
J Invest Dermatol. 2017 Jul;137(7):1562-1568
pubmed: 28392344
Mol Med Rep. 2015 Sep;12(3):4141-4148
pubmed: 26082314
Immunology. 1989 Feb;66(2):196-200
pubmed: 2784408
Arthritis Rheum. 1978 Jul-Aug;21(6):694-8
pubmed: 736999
Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:483-93
pubmed: 12432938
J Virol. 2010 Oct;84(20):10877-87
pubmed: 20686047
Pharmacol Rep. 2006 Jul-Aug;58(4):473-92
pubmed: 16963793
Semin Arthritis Rheum. 2003 Dec;33(3):155-67
pubmed: 14671726
Scand J Rheumatol. 2011;40(4):308-16
pubmed: 21417548
J Clin Invest. 2017 Mar 1;127(3):737-749
pubmed: 28248203
Arthritis Rheum. 1981 Dec;24(12):1582-6
pubmed: 7326073
Arthritis Rheum. 1977 Apr;20(3):785-91
pubmed: 324481
Arthritis Res Ther. 2019 Jan 21;21(1):29
pubmed: 30665457
J Gen Virol. 1982 Dec;63(2):359-63
pubmed: 6818330
J Neuroinflammation. 2016 Jan 18;13:11
pubmed: 26780827
Adv Exp Med Biol. 2002;507:177-84
pubmed: 12664583
Arthritis Rheum. 1994 May;37(5):653-61
pubmed: 8185692
Inflamm Res. 2001 Feb;50(2):65-72
pubmed: 11289656
Nature. 1977 Jun 2;267(5610):457-9
pubmed: 876363
Arthritis Care Res (Hoboken). 2018 Oct;70(10):1501-1508
pubmed: 29361202
J Immunol. 2010 May 15;184(10):5914-27
pubmed: 20404278
J Rheumatol. 1998 Mar;25(3):433-40
pubmed: 9517759
PLoS Negl Trop Dis. 2015 Mar 11;9(3):e0003603
pubmed: 25760632
Prostaglandins Leukot Essent Fatty Acids. 2000 Jan;62(1):1-5
pubmed: 10765972

Auteurs

Yosra Bedoui (Y)

Unité mixte de recherche sur les processus infectieux en milieu insulaire tropical, INSERM U1187, CNRS 9192, IRD 249, Université de La Réunion-Plateforme Technologique CYROI Sainte-Clotilde, Île de La Réunion, France.
Laboratoire d'immunologie clinique et expérimentale de la zone de l'océan indien CHU La Réunion site Félix Guyon, Allée des Topazes, Saint Denis de La Réunion, France.

Axelle Septembre-Malaterre (A)

Unité de recherche Etudes Pharmaco-Immunologie, Université de la Réunion, CHU La Réunion site Félix Guyon, Allée des Topazes, Saint Denis de La Réunion, France.

Claude Giry (C)

Laboratoire de biologie, CNR associé des arbovirus, CHU La Réunion site Félix Guyon, Allée des Topazes, Saint Denis de La Réunion, France.

Marie-Christine Jaffar-Bandjee (MC)

Laboratoire de biologie, CNR associé des arbovirus, CHU La Réunion site Félix Guyon, Allée des Topazes, Saint Denis de La Réunion, France.

Jimmy Selambarom (J)

Unité mixte de recherche sur les processus infectieux en milieu insulaire tropical, INSERM U1187, CNRS 9192, IRD 249, Université de La Réunion-Plateforme Technologique CYROI Sainte-Clotilde, Île de La Réunion, France.

Pascale Guiraud (P)

Unité mixte de recherche sur les processus infectieux en milieu insulaire tropical, INSERM U1187, CNRS 9192, IRD 249, Université de La Réunion-Plateforme Technologique CYROI Sainte-Clotilde, Île de La Réunion, France.

Philippe Gasque (P)

Unité mixte de recherche sur les processus infectieux en milieu insulaire tropical, INSERM U1187, CNRS 9192, IRD 249, Université de La Réunion-Plateforme Technologique CYROI Sainte-Clotilde, Île de La Réunion, France.
Laboratoire d'immunologie clinique et expérimentale de la zone de l'océan indien CHU La Réunion site Félix Guyon, Allée des Topazes, Saint Denis de La Réunion, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH